{"publisher":"Metformin Co","product":"Metformin ER","preparedAt":"2026-11-07","reviewStatus":"Research drafts; medical review has not been claimed","facts":[{"label":"Research finding 1","text":"In the 15-year follow-up of the Diabetes Prevention Program Outcomes Study, the cumulative incidences of diabetes at year 15 were 55% in the lifestyle group, 56% in the metformin group, and 62% in the placebo group.","href":"https://pubmed.ncbi.nlm.nih.gov/26377054/"},{"label":"Research finding 2","text":"A systematic review and meta-analysis of studies comparing metformin users with non-diabetics or diabetics on other therapies reported that diabetics taking metformin had significantly lower all-cause mortality than non-diabetics (hazard ratio 0.93, 95% CI 0.88-0.99), and noted that differences in baseline characteristics had the potential to bias findings.","href":"https://pubmed.ncbi.nlm.nih.gov/28802803/"},{"label":"Research finding 3","text":"A review concluded that developments in the evidence, including replication attempts and clinical trials of metformin in individuals without type II diabetes, generally illustrate an emerging uncertainty in the anti-aging potential of metformin. Its conflict-of-interest statement lists consulting or advisory relationships between one author and Boehringer-Ingelheim and Novartis.","href":"https://pubmed.ncbi.nlm.nih.gov/40582648/"},{"label":"Research finding 4","text":"The MASTERS randomized, double-blind trial gave healthy older adults 1,700 mg/day metformin (N = 46) or placebo (N = 48) throughout 14 weeks of supervised progressive resistance exercise training, and concluded that metformin negatively impacts the hypertrophic response to resistance training in healthy older individuals.","href":"https://pubmed.ncbi.nlm.nih.gov/31557380/"},{"label":"Research finding 5","text":"The MA.32 randomized trial in patients with high-risk operable breast cancer without diabetes concluded that adding metformin versus placebo to standard breast cancer treatment did not significantly improve invasive disease-free survival.","href":"https://pubmed.ncbi.nlm.nih.gov/35608580/"},{"label":"Research finding 6","text":"A secondary analysis of the randomized Diabetes Prevention Program and its Outcomes Study (metformin 850 mg twice daily) concluded that long-term use of metformin was associated with biochemical B12 deficiency and anemia and that routine testing of vitamin B12 levels in metformin-treated patients should be considered.","href":"https://pubmed.ncbi.nlm.nih.gov/26900641/"},{"label":"Research finding 7","text":"An FDA patient page on off-label use says FDA has not determined that an approved drug is safe and effective for an unapproved use.","href":"https://www.fda.gov/patients/learn-about-expanded-access-and-other-treatment-options/understanding-unapproved-use-approved-drugs-label"}],"sources":[{"title":"Metformin hydrochloride extended-release tablets prescribing information","href":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=96c8a89d-99db-24b1-e053-2a95a90ac2b8"},{"title":"Drugs@FDA: Glucophage XR (metformin hydrochloride) application overview","href":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021202"},{"title":"FDA: understanding unapproved use of approved drugs (off label)","href":"https://www.fda.gov/patients/learn-about-expanded-access-and-other-treatment-options/understanding-unapproved-use-approved-drugs-label"},{"title":"FDA: updates and press announcements on NDMA in metformin","href":"https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-announcements-ndma-metformin"},{"title":"NIDDK: the Diabetes Prevention Program","href":"https://www.niddk.nih.gov/about-niddk/research-areas/diabetes/diabetes-prevention-program-dpp"}],"guides":[{"title":"What the Diabetes Prevention Program measured for metformin and lifestyle","url":"https://metforminco.com/research-guides/diabetes-prevention-program-what-it-measured","description":"What the Diabetes Prevention Program trial measured when it compared metformin, a lifestyle program and placebo in people with elevated glucose.","date":"2026-11-10"},{"title":"Metformin ER, kidney function, contrast imaging, surgery and alcohol: what the sources say","url":"https://metforminco.com/research-guides/kidney-function-contrast-surgery-alcohol-and-metformin","description":"What the prescribing information and its patient information state about eGFR, contrast imaging, surgery, alcohol, hepatic impairment and fluid loss.","date":"2026-11-10"},{"title":"Metformin ER lactic acidosis boxed warning: what the label says","url":"https://metforminco.com/research-guides/lactic-acidosis-boxed-warning-what-the-label-says","description":"The boxed warning wording, listed risk factors and interactions, and how a Cochrane review, a cohort study and a meta-analysis reported on it.","date":"2026-11-10"},{"title":"Metformin, aging and longevity: what the evidence shows","url":"https://metforminco.com/research-guides/metformin-aging-and-longevity-what-the-evidence-shows","description":"What observational studies, randomized trials and reviews report on metformin, aging and survival, and what each one cannot show.","date":"2026-11-10"},{"title":"Metformin and weight: what trials measured","url":"https://metforminco.com/research-guides/metformin-and-weight-what-trials-measured","description":"What the prescribing information, trial follow-up and meta-analyses report about weight and metformin, by the group each one studied.","date":"2026-11-10"},{"title":"What does the metformin ER label say about its indication and dosing?","url":"https://metforminco.com/research-guides/metformin-er-label-indication-and-dosing","description":"What the prescribing information states on the indication, the dosing wording, kidney checks and listed side effects, without dose advice.","date":"2026-11-10"},{"title":"Metformin ER and the NDMA recall: what the FDA pages say","url":"https://metforminco.com/research-guides/metformin-er-ndma-recall-what-the-fda-says","description":"What FDA pages from 2020 and 2021 say about NDMA in some extended-release metformin, and what they cannot tell you today.","date":"2026-11-10"},{"title":"Metformin for PCOS and other conditions: what studies measured","url":"https://metforminco.com/research-guides/metformin-pcos-and-other-conditions-what-studies-measured","description":"What studies report for metformin in PCOS, gestational diabetes, antipsychotic weight gain, breast cancer, heart disease and cancer incidence.","date":"2026-11-10"},{"title":"Metformin in pregnancy and breastfeeding: what the label and studies state","url":"https://metforminco.com/research-guides/metformin-pregnancy-and-breastfeeding","description":"What the ER tablet label and its patient information state about metformin in pregnancy, breastfeeding and ovulation, plus two studies.","date":"2026-11-10"},{"title":"Metformin ER side effects: what the label and comparison studies report","url":"https://metforminco.com/research-guides/metformin-side-effects-and-extended-release-tolerability","description":"The label's listed adverse reactions and percentages, plus studies comparing extended-release with immediate-release metformin.","date":"2026-11-10"},{"title":"Vitamin B12 and metformin: what the label and studies report","url":"https://metforminco.com/research-guides/vitamin-b12-and-metformin-what-studies-report","description":"What one generic label, a randomized trial analysis and a review of observational studies report about metformin and vitamin B12.","date":"2026-11-10"},{"title":"What is metformin ER and how might it work?","url":"https://metforminco.com/research-guides/what-metformin-er-is-and-how-it-might-work","description":"What a biguanide extended-release tablet is, what the label says it is for, and how review abstracts word the proposed mechanisms.","date":"2026-11-10"}]}